U.K. preparing for value-based drug-pricing system

03/24/2013 | Reuters

Beginning in 2014, Britain's National Institute for Health and Clinical Excellence will approve and price drugs based on broader measures, including the benefits to society. Firms with innovative, badly needed or highly effective medications, for example, could command higher prices. The new value-based initiative will replace the current system that caps the maximum return on investments that drug companies can earn.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC